 |
At a meeting held Thursday, Food and Drug Administration's (FDA) Office of Cellular, Tissue and Gene Therapies Advisory Committee said that there is substantial evidence of efficacy and safety of Dendreon Corp.'s Provenge (sipuleucel-T) for the treatment of patients with prostate cancer.
|
